Medoxem (Cefuroxime Axetil)

Cefuroxime axetil is a broad‑spectrum cephalosporin used to treat bacterial infections of the respiratory, urinary, and skin systems.

• Upper respiratory tract infections: reduces bacterial load and alleviates symptoms such as cough and sore throat.
• Lower respiratory tract infections: effective against pathogens causing bronchitis and pneumonia.
• Urinary tract infections: eradicates common uropathogens and helps resolve dysuria and frequency.
• Skin and soft tissue infections: treats cellulitis, impetigo and wound infections caused by susceptible bacteria.
• Sinusitis: clears sinus inflammation by targeting the causative bacteria.
• Otitis media: improves middle‑ear infection outcomes in children and adults.

• Cefuroxime axetil is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to cefuroxime, the active moiety. Cefuroxime binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. The drug exhibits time‑dependent killing and retains activity against many Gram‑positive and Gram‑negative organisms, including strains resistant to earlier‑generation penicillins.

Cefuroxime axetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools that may be self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.
• Headache: transient headache without neurological signs.
• Rash: mild skin erythema or itching.
• Vomiting: occasional emesis, usually not severe.

Serious or Rare Side Effects

• Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention.
• Anaphylaxis: life‑threatening allergic reaction with hives, swelling, and respiratory distress.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Blood dyscrasias: neutropenia, thrombocytopenia, or hemolytic anemia.
• Hepatic enzyme elevation: significant increase in liver transaminases.
• Renal impairment: acute kidney injury in susceptible patients.

Before prescribing cefuroxime axetil, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function and adjust dose if creatinine clearance is reduced.
• Hepatic impairment: monitor liver enzymes in patients with existing liver disease.
• Allergy history: avoid in patients with known severe hypersensitivity to cephalosporins or penicillins.
• Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Concomitant anticoagulants: monitor INR closely when combined with warfarin due to possible enhanced effect.
• Drug interactions: review all concomitant medications for potential interactions that may affect efficacy or toxicity.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Cefuroxime axetil can interact with other medicines, influencing its absorption or activity.

Major Interactions (Avoid)

• Probenecid: decreases renal excretion, increasing cefuroxime plasma concentrations.
• Antacids containing aluminum or magnesium: bind the drug and markedly reduce oral absorption.
• Warfarin: may potentiate anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible reduction in contraceptive efficacy, advise additional non‑hormonal methods.
• Diuretics (e.g., furosemide): may affect renal clearance, requiring renal function monitoring.
• Metformin: reduced renal clearance may increase metformin levels, monitor for lactic acidosis.